| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Glomerular Basement Membrane Disease | 22 | 2023 | 23 | 7.020 |
Why?
|
| Collagen Type IV | 33 | 2021 | 48 | 5.060 |
Why?
|
| Autoantibodies | 20 | 2023 | 103 | 4.250 |
Why?
|
| Autoantigens | 20 | 2021 | 81 | 3.200 |
Why?
|
| Glomerulonephritis, Membranous | 5 | 2022 | 9 | 2.750 |
Why?
|
| Nephritis, Hereditary | 14 | 2014 | 14 | 2.520 |
Why?
|
| Immunoglobulin G | 11 | 2023 | 237 | 2.480 |
Why?
|
| Glomerular Basement Membrane | 6 | 2019 | 9 | 1.960 |
Why?
|
| Laminin | 8 | 2023 | 61 | 1.880 |
Why?
|
| Glomerulonephritis | 6 | 2016 | 13 | 1.480 |
Why?
|
| Kidney | 10 | 2021 | 337 | 1.180 |
Why?
|
| Isoantibodies | 6 | 2013 | 7 | 1.160 |
Why?
|
| Epitopes | 9 | 2021 | 148 | 1.070 |
Why?
|
| Kidney Glomerulus | 10 | 2022 | 84 | 1.020 |
Why?
|
| Kidney Transplantation | 5 | 2013 | 86 | 0.970 |
Why?
|
| Disease Models, Animal | 9 | 2013 | 1371 | 0.830 |
Why?
|
| Basement Membrane | 10 | 2022 | 28 | 0.800 |
Why?
|
| Hemoptysis | 1 | 2021 | 3 | 0.790 |
Why?
|
| Complement Activation | 2 | 2022 | 13 | 0.780 |
Why?
|
| Mice, Transgenic | 9 | 2019 | 617 | 0.710 |
Why?
|
| Antigen-Antibody Complex | 2 | 2022 | 19 | 0.680 |
Why?
|
| Animals | 38 | 2023 | 15081 | 0.660 |
Why?
|
| Epitope Mapping | 5 | 2013 | 31 | 0.650 |
Why?
|
| Lupus Nephritis | 2 | 2016 | 23 | 0.640 |
Why?
|
| Mice | 23 | 2021 | 5913 | 0.610 |
Why?
|
| Heparitin Sulfate | 2 | 2016 | 23 | 0.600 |
Why?
|
| Humans | 44 | 2023 | 37093 | 0.590 |
Why?
|
| Immunoglobulin A | 2 | 2008 | 58 | 0.570 |
Why?
|
| Proteins | 4 | 2005 | 369 | 0.560 |
Why?
|
| Antibody Specificity | 3 | 2013 | 79 | 0.540 |
Why?
|
| Collagen | 6 | 2005 | 172 | 0.540 |
Why?
|
| Kidney Failure, Chronic | 4 | 2021 | 233 | 0.520 |
Why?
|
| Receptors, Fc | 1 | 2013 | 7 | 0.470 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2013 | 21 | 0.470 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2012 | 259 | 0.470 |
Why?
|
| Plasminogen | 3 | 2004 | 10 | 0.440 |
Why?
|
| Autoimmune Diseases | 3 | 2015 | 57 | 0.440 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 1015 | 0.430 |
Why?
|
| Immune Tolerance | 1 | 2013 | 65 | 0.430 |
Why?
|
| Nephrotic Syndrome | 1 | 2012 | 10 | 0.410 |
Why?
|
| Protein Structure, Tertiary | 9 | 2013 | 408 | 0.410 |
Why?
|
| Antigens | 2 | 2008 | 56 | 0.400 |
Why?
|
| Mice, Knockout | 11 | 2016 | 933 | 0.350 |
Why?
|
| Protein Structure, Quaternary | 5 | 2013 | 64 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 4 | 2008 | 290 | 0.330 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 2 | 2009 | 3 | 0.320 |
Why?
|
| Nephritis | 2 | 2010 | 6 | 0.320 |
Why?
|
| Epitopes, B-Lymphocyte | 2 | 2008 | 12 | 0.310 |
Why?
|
| Protein Binding | 8 | 2008 | 972 | 0.310 |
Why?
|
| Mice, Inbred C57BL | 7 | 2016 | 1609 | 0.300 |
Why?
|
| Isoantigens | 1 | 2007 | 5 | 0.300 |
Why?
|
| Complement Factor H | 2 | 2016 | 5 | 0.280 |
Why?
|
| Antibodies | 2 | 2010 | 141 | 0.280 |
Why?
|
| Immunity, Innate | 1 | 2007 | 149 | 0.280 |
Why?
|
| Male | 14 | 2021 | 20025 | 0.260 |
Why?
|
| Hemostasis | 1 | 2005 | 6 | 0.260 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2005 | 20 | 0.260 |
Why?
|
| Immunoglobulin Allotypes | 1 | 2005 | 5 | 0.260 |
Why?
|
| Protein Conformation | 7 | 2010 | 389 | 0.260 |
Why?
|
| Collagen Type I | 1 | 2005 | 30 | 0.250 |
Why?
|
| Blood Proteins | 3 | 2005 | 66 | 0.240 |
Why?
|
| Disease Progression | 3 | 2021 | 601 | 0.240 |
Why?
|
| Complement C3 | 2 | 2016 | 16 | 0.240 |
Why?
|
| Lung | 2 | 2021 | 446 | 0.240 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2012 | 295 | 0.240 |
Why?
|
| Podocytes | 3 | 2009 | 35 | 0.230 |
Why?
|
| Glycoproteins | 1 | 2004 | 106 | 0.230 |
Why?
|
| Female | 11 | 2023 | 20969 | 0.230 |
Why?
|
| Glycosaminoglycans | 2 | 2004 | 22 | 0.220 |
Why?
|
| Thrombospondins | 1 | 2022 | 3 | 0.220 |
Why?
|
| Proteinuria | 2 | 2021 | 50 | 0.210 |
Why?
|
| Mice, Inbred DBA | 2 | 2013 | 71 | 0.210 |
Why?
|
| Complement System Proteins | 1 | 2022 | 21 | 0.210 |
Why?
|
| Albuminuria | 2 | 2013 | 76 | 0.210 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2004 | 22 | 0.210 |
Why?
|
| Receptors, Phospholipase A2 | 1 | 2021 | 1 | 0.200 |
Why?
|
| Protein Isoforms | 5 | 2010 | 130 | 0.200 |
Why?
|
| Fumarates | 1 | 2021 | 11 | 0.200 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2010 | 448 | 0.200 |
Why?
|
| Saimiri | 1 | 2021 | 6 | 0.200 |
Why?
|
| Membrane Glycoproteins | 2 | 2016 | 211 | 0.200 |
Why?
|
| Muscle, Smooth | 1 | 2001 | 58 | 0.190 |
Why?
|
| Creatinine | 1 | 2021 | 103 | 0.190 |
Why?
|
| Transplantation, Homologous | 2 | 2013 | 36 | 0.190 |
Why?
|
| Cattle | 4 | 2013 | 477 | 0.180 |
Why?
|
| Models, Molecular | 5 | 2008 | 808 | 0.180 |
Why?
|
| Animals, Newborn | 2 | 2019 | 343 | 0.180 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 2005 | 364 | 0.170 |
Why?
|
| Immunity, Humoral | 1 | 2019 | 24 | 0.170 |
Why?
|
| Prognosis | 1 | 2021 | 739 | 0.160 |
Why?
|
| Plasma | 1 | 1998 | 31 | 0.160 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1130 | 0.150 |
Why?
|
| Amino Acid Sequence | 6 | 2013 | 1180 | 0.150 |
Why?
|
| Molecular Sequence Data | 6 | 2013 | 1568 | 0.150 |
Why?
|
| Aged | 4 | 2021 | 6741 | 0.140 |
Why?
|
| Complement C3b | 1 | 2016 | 2 | 0.140 |
Why?
|
| Agrin | 1 | 2016 | 5 | 0.140 |
Why?
|
| Retrospective Studies | 2 | 2021 | 2026 | 0.140 |
Why?
|
| Receptors, Complement | 1 | 2016 | 2 | 0.140 |
Why?
|
| Complement Pathway, Alternative | 1 | 2016 | 2 | 0.140 |
Why?
|
| Static Electricity | 1 | 2016 | 78 | 0.140 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2013 | 269 | 0.140 |
Why?
|
| Dimerization | 3 | 2008 | 112 | 0.140 |
Why?
|
| Blister | 1 | 2015 | 2 | 0.130 |
Why?
|
| Peroxidase | 2 | 2013 | 49 | 0.130 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2008 | 286 | 0.130 |
Why?
|
| Cell Line | 4 | 2005 | 1354 | 0.130 |
Why?
|
| Pregnancy | 2 | 2019 | 1549 | 0.130 |
Why?
|
| Oligoribonucleotides, Antisense | 1 | 2014 | 3 | 0.130 |
Why?
|
| Rabbits | 4 | 2008 | 283 | 0.120 |
Why?
|
| Postoperative Complications | 2 | 2013 | 210 | 0.120 |
Why?
|
| Skin | 1 | 2015 | 174 | 0.120 |
Why?
|
| Smoking | 1 | 2021 | 940 | 0.120 |
Why?
|
| Adult | 4 | 2021 | 11712 | 0.120 |
Why?
|
| Sulfur Compounds | 1 | 2013 | 7 | 0.120 |
Why?
|
| X Chromosome | 2 | 2006 | 30 | 0.120 |
Why?
|
| Imines | 1 | 2013 | 10 | 0.120 |
Why?
|
| Binding Sites, Antibody | 2 | 2010 | 20 | 0.120 |
Why?
|
| Blood Volume Determination | 1 | 2013 | 1 | 0.120 |
Why?
|
| Blood Volume | 1 | 2013 | 5 | 0.120 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2013 | 11 | 0.120 |
Why?
|
| Kidney Function Tests | 1 | 2013 | 29 | 0.120 |
Why?
|
| Renal Circulation | 1 | 2013 | 21 | 0.120 |
Why?
|
| Recombinant Proteins | 4 | 2008 | 515 | 0.110 |
Why?
|
| RNA, Messenger | 4 | 2012 | 1207 | 0.110 |
Why?
|
| Haplorhini | 1 | 2013 | 22 | 0.110 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 42 | 0.110 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2012 | 1 | 0.110 |
Why?
|
| Microscopic Polyangiitis | 1 | 2012 | 1 | 0.110 |
Why?
|
| Biopsy | 2 | 2015 | 164 | 0.110 |
Why?
|
| Paraquat | 1 | 2012 | 21 | 0.110 |
Why?
|
| Mice, Congenic | 1 | 2012 | 2 | 0.110 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 70 | 0.100 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2012 | 57 | 0.100 |
Why?
|
| Pulmonary Alveoli | 1 | 2012 | 27 | 0.100 |
Why?
|
| Receptors, IgG | 1 | 2012 | 50 | 0.100 |
Why?
|
| Ascorbic Acid | 1 | 2012 | 66 | 0.100 |
Why?
|
| Middle Aged | 3 | 2021 | 10129 | 0.100 |
Why?
|
| Extracellular Matrix | 2 | 2013 | 115 | 0.100 |
Why?
|
| Immunization | 1 | 2012 | 92 | 0.100 |
Why?
|
| Binding Sites | 2 | 2008 | 651 | 0.100 |
Why?
|
| Precipitin Tests | 2 | 2002 | 52 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 2013 | 167 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 893 | 0.100 |
Why?
|
| Histidine | 2 | 2004 | 42 | 0.100 |
Why?
|
| Surface Properties | 2 | 2004 | 130 | 0.100 |
Why?
|
| Chromosomes, Human, X | 1 | 2010 | 22 | 0.090 |
Why?
|
| Peptide Fragments | 3 | 2004 | 308 | 0.090 |
Why?
|
| Mesangial Cells | 2 | 2009 | 9 | 0.090 |
Why?
|
| Cross Reactions | 1 | 2010 | 83 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2010 | 83 | 0.090 |
Why?
|
| Models, Biological | 3 | 2008 | 677 | 0.090 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2009 | 42 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2002 | 859 | 0.090 |
Why?
|
| Th1 Cells | 1 | 2009 | 92 | 0.090 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2009 | 88 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2014 | 426 | 0.080 |
Why?
|
| Hydra | 1 | 2008 | 4 | 0.080 |
Why?
|
| Binding, Competitive | 2 | 2000 | 111 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2008 | 31 | 0.080 |
Why?
|
| Betamethasone | 1 | 2008 | 2 | 0.080 |
Why?
|
| Cerebral Ventricles | 1 | 2008 | 23 | 0.080 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2008 | 12 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2016 | 1908 | 0.070 |
Why?
|
| Models, Immunological | 1 | 2007 | 21 | 0.070 |
Why?
|
| Neuroglia | 1 | 2008 | 124 | 0.070 |
Why?
|
| Transplantation Chimera | 1 | 2007 | 7 | 0.070 |
Why?
|
| Heparin | 2 | 1998 | 35 | 0.070 |
Why?
|
| Fibroblast Growth Factors | 1 | 2007 | 33 | 0.070 |
Why?
|
| Neuromuscular Junction | 1 | 2007 | 33 | 0.070 |
Why?
|
| Motor Neurons | 1 | 2007 | 83 | 0.070 |
Why?
|
| Integrin alpha1 | 1 | 2006 | 2 | 0.070 |
Why?
|
| Integrin alpha1beta1 | 1 | 2006 | 2 | 0.070 |
Why?
|
| Survival | 1 | 2006 | 8 | 0.070 |
Why?
|
| Integrin alpha3beta1 | 1 | 2006 | 1 | 0.070 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2007 | 80 | 0.070 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2006 | 12 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 149 | 0.070 |
Why?
|
| Cerebral Cortex | 1 | 2008 | 290 | 0.070 |
Why?
|
| Transplantation Immunology | 1 | 2005 | 5 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2005 | 40 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 60 | 0.070 |
Why?
|
| Diabetic Nephropathies | 1 | 2006 | 61 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2005 | 38 | 0.070 |
Why?
|
| Protein Denaturation | 1 | 2005 | 43 | 0.070 |
Why?
|
| Hemostatics | 1 | 2005 | 8 | 0.070 |
Why?
|
| Phenotype | 2 | 2005 | 689 | 0.060 |
Why?
|
| Blood Coagulation | 1 | 2005 | 23 | 0.060 |
Why?
|
| Macromolecular Substances | 1 | 2005 | 96 | 0.060 |
Why?
|
| Immunoassay | 1 | 2005 | 61 | 0.060 |
Why?
|
| Recurrence | 1 | 2005 | 131 | 0.060 |
Why?
|
| Solutions | 1 | 2004 | 62 | 0.060 |
Why?
|
| Adsorption | 1 | 2004 | 68 | 0.060 |
Why?
|
| Proline | 1 | 2004 | 43 | 0.060 |
Why?
|
| Catalysis | 1 | 2004 | 179 | 0.060 |
Why?
|
| Mutation | 2 | 2016 | 1095 | 0.060 |
Why?
|
| Transfection | 1 | 2005 | 523 | 0.060 |
Why?
|
| Chimera | 1 | 2003 | 15 | 0.060 |
Why?
|
| Ligands | 1 | 2005 | 349 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2005 | 219 | 0.060 |
Why?
|
| Rats, Inbred WKY | 1 | 2023 | 23 | 0.060 |
Why?
|
| Gene Expression | 1 | 2007 | 674 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2003 | 46 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2005 | 753 | 0.050 |
Why?
|
| Cells, Cultured | 4 | 2007 | 1518 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2015 | 189 | 0.050 |
Why?
|
| Crystallography, X-Ray | 1 | 2002 | 265 | 0.050 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2001 | 35 | 0.050 |
Why?
|
| Urinary Bladder | 1 | 2001 | 29 | 0.050 |
Why?
|
| Cross-Linking Reagents | 2 | 2013 | 51 | 0.050 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2001 | 78 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2001 | 209 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2001 | 201 | 0.050 |
Why?
|
| Immunodominant Epitopes | 1 | 2000 | 27 | 0.050 |
Why?
|
| Immune Sera | 2 | 1999 | 59 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2014 | 513 | 0.050 |
Why?
|
| Protein Subunits | 2 | 2015 | 87 | 0.050 |
Why?
|
| Aorta | 1 | 2001 | 167 | 0.050 |
Why?
|
| Antibody Affinity | 1 | 2000 | 25 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2002 | 515 | 0.040 |
Why?
|
| Chromatography, Affinity | 1 | 2000 | 67 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2013 | 67 | 0.040 |
Why?
|
| Dermatan Sulfate | 1 | 1998 | 1 | 0.040 |
Why?
|
| Chondroitin Sulfates | 1 | 1998 | 9 | 0.040 |
Why?
|
| Reactive Oxygen Species | 2 | 2014 | 461 | 0.040 |
Why?
|
| Base Sequence | 2 | 1999 | 997 | 0.040 |
Why?
|
| Metals | 1 | 1998 | 98 | 0.040 |
Why?
|
| Thermodynamics | 1 | 1998 | 216 | 0.040 |
Why?
|
| Chlorides | 1 | 1997 | 56 | 0.040 |
Why?
|
| Molecular Weight | 1 | 1997 | 167 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 1039 | 0.040 |
Why?
|
| Biosensing Techniques | 1 | 1998 | 86 | 0.040 |
Why?
|
| Receptors, Complement 3b | 1 | 2016 | 4 | 0.040 |
Why?
|
| Isoelectric Point | 1 | 1996 | 9 | 0.030 |
Why?
|
| Kinetics | 1 | 1998 | 708 | 0.030 |
Why?
|
| Cell Adhesion | 2 | 2008 | 212 | 0.030 |
Why?
|
| Plasma Exchange | 1 | 2015 | 5 | 0.030 |
Why?
|
| Rats | 1 | 2023 | 3483 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1996 | 191 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 1996 | 183 | 0.030 |
Why?
|
| Disulfides | 1 | 1996 | 77 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 325 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2015 | 86 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2007 | 661 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 67 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 400 | 0.030 |
Why?
|
| Peroxidases | 1 | 2013 | 15 | 0.030 |
Why?
|
| Fibrosis | 1 | 2014 | 159 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2013 | 61 | 0.030 |
Why?
|
| DNA Primers | 2 | 2008 | 286 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2013 | 40 | 0.030 |
Why?
|
| Oxidative Stress | 2 | 2012 | 938 | 0.030 |
Why?
|
| Heme | 1 | 2013 | 70 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 61 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2013 | 106 | 0.030 |
Why?
|
| Neutrophil Activation | 1 | 2012 | 4 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 84 | 0.030 |
Why?
|
| Founder Effect | 1 | 2012 | 9 | 0.030 |
Why?
|
| Zebrafish | 1 | 2013 | 128 | 0.030 |
Why?
|
| F2-Isoprostanes | 1 | 2012 | 20 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 260 | 0.030 |
Why?
|
| Albumins | 1 | 2012 | 26 | 0.030 |
Why?
|
| Drosophila melanogaster | 1 | 2013 | 180 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2012 | 129 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 562 | 0.030 |
Why?
|
| Models, Animal | 1 | 2012 | 134 | 0.030 |
Why?
|
| Neutrophils | 1 | 2012 | 131 | 0.030 |
Why?
|
| Peptides | 1 | 2013 | 320 | 0.020 |
Why?
|
| Pedigree | 1 | 2010 | 79 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 1742 | 0.020 |
Why?
|
| Heterozygote | 1 | 2010 | 93 | 0.020 |
Why?
|
| Algorithms | 1 | 2013 | 465 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 935 | 0.020 |
Why?
|
| Genes, RAG-1 | 1 | 2009 | 2 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2009 | 48 | 0.020 |
Why?
|
| Ovalbumin | 1 | 2009 | 47 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2009 | 27 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2009 | 53 | 0.020 |
Why?
|
| Endothelium | 1 | 2009 | 31 | 0.020 |
Why?
|
| Motor Activity | 1 | 2012 | 418 | 0.020 |
Why?
|
| Liver | 1 | 2012 | 479 | 0.020 |
Why?
|
| Chemokines | 1 | 2009 | 97 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2008 | 18 | 0.020 |
Why?
|
| Cognition | 1 | 2012 | 398 | 0.020 |
Why?
|
| Morphogenesis | 1 | 2008 | 50 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2008 | 142 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2008 | 119 | 0.020 |
Why?
|
| Pericytes | 1 | 2008 | 22 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2008 | 129 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2008 | 91 | 0.020 |
Why?
|
| Fibronectins | 1 | 2008 | 66 | 0.020 |
Why?
|
| Fetus | 1 | 2008 | 105 | 0.020 |
Why?
|
| Gestational Age | 1 | 2008 | 190 | 0.020 |
Why?
|
| Lac Operon | 1 | 2007 | 21 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2007 | 74 | 0.020 |
Why?
|
| Myoblasts | 1 | 2007 | 27 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 31 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 116 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 103 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2007 | 101 | 0.020 |
Why?
|
| Presynaptic Terminals | 1 | 2007 | 53 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2007 | 207 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 550 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 448 | 0.020 |
Why?
|
| Integrins | 1 | 2006 | 51 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 161 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2006 | 139 | 0.020 |
Why?
|
| Cell Division | 1 | 2006 | 307 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2006 | 127 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2008 | 894 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2006 | 94 | 0.020 |
Why?
|
| Anxiety | 1 | 2012 | 754 | 0.020 |
Why?
|
| Glucose | 1 | 2006 | 230 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 237 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 2379 | 0.010 |
Why?
|
| Aging | 1 | 2008 | 664 | 0.010 |
Why?
|
| Cell Movement | 1 | 2006 | 571 | 0.010 |
Why?
|
| Child | 1 | 2010 | 3131 | 0.010 |
Why?
|
| Capillary Permeability | 1 | 2000 | 30 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2006 | 807 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 1198 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2000 | 188 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 4268 | 0.010 |
Why?
|
| Protein Folding | 1 | 2000 | 127 | 0.010 |
Why?
|
| Adolescent | 1 | 2010 | 5363 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2006 | 2231 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2000 | 409 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1999 | 89 | 0.010 |
Why?
|